• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Stock Trend Alerts

Essential Market Ideas and Investing Strategies

  • Newsletter Reviews
  • Hot Stocks
  • Technology
  • Financial News
  • Secrets of the Pros
  • Analysis
Home » The #1 DNA Stock Leading the Genomic Revolution?

The #1 DNA Stock Leading the Genomic Revolution?

Precision medicine just took a HUGE step forward…

CRISPR gene-editing technology was used on humans for the first time.

Biotech company Intellia Therapeutics Inc. (Nasdaq: NTLA) achieved the milestone in a clinical trial in June.

CRISPR editing was used to treat people with a rare protein disorder. Not only was the treatment safe, but preliminary results were also promising.

Participants who received the highest dose saw an 87% drop in the therapy’s targeted protein.

CRISPR has been the biggest development from the biotech industry in recent years. So much so that its pioneers received a Nobel Prize in 2020. And for good reason…

It means no more monthly trips to the doctor.

THE GENE-EDITING INDUSTRY IS GROWING RAPIDLY

CRISPR technology targets common diseases where people inherit the wrong genes.

It aims to cure these diseases by replacing faulty genes with healthy variant. This gets to the root of the problem: fixing the gene for good.

But past CRISPR trials had one common problem.

Since the technology was applied to genomes removed from the human body, certain cell types died off and lost function when grown in an artificial environment.

Gene editing inside the human body (in vivo) can mitigate this problem by revising the genome in its native tissue.

Scientists believe Intellia’s in vivo gene-editing results open the door to treating a wider range of diseases, including HIV.

This is a BIG deal!

[Discover: The off the radar Small-Cap Stock at the center of an Era-Defining Technology]

Intellia’s stock doubled in a matter of days after its announcement.

NTLA Soared Over 100% Last Week

(source: Bloomberg.)

But if you missed out on Intellia’s rise, there’s no need to sweat.

CRISPR gene editing is just a subset of the rapidly growing genomics market.

This industry is poised to more than triple between now and 2030.

(source: Precedence Research.)

[Breakthrough: Scientists Predict this Industry Could Grow Nearly 200,000% in Just Four Years]

To get exposure to the genomics industry, you can buy shares of the Global X Genomics and Biotechnology ETF (Nasdaq: GNOM).

Or…

You can join our subscribers and find out about our favorite stock pick leading the genomic revolution.

Regards,

Stephan Fernandez

[See Also: “Imperium” – The Microchip Company Powering the 199,000% DNA Mega Trend]

Read more from Steve Fernandez at BanyanHill.com

You Might Also Like...

  • Does the Massive Hype of Next Week's Robinhood IPO Outweigh the Risk?
  • Could This Be One of the Best Crypto Buying Opportunities of the Year?
  • The Bullish Side of The Great Supply Chain Snarl
  • The Untold Secret of The World's Most Valuable Company...

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Subscribe to Stock Trend Alerts

By submitting your email address, you give Stock Trend Alerts permission to deliver investment research to your email inbox. Privacy Policy | How It Works

Popular Posts

  • Martin Weiss Docket No. OP–1670: 12 Inflation-Beating Stocks
  • Jim Rickards – The Return of American Energy: Profit from the Green Lie
  • Andrew Zatlin: Biden’s Puppet Master Exposed and How to Opt Out of the Digital Dollar
  • Why 2023 Could Kick Off a “Cash Frenzy” in Stocks
  • Dylan Jovine 21st Century Battlefield: 4 Companies Changing Warfare
  • BREAKING: Military to spend billions on “Living Missile”
  • Dylan Jovine Search & Destroy: 3 AI Software Stocks Revolutionizing Warfare
  • Infinite Energy Stock: The Tiny Company Dominating Tesla in the Trillion-Dollar Green Energy Race

Recent Posts

  • 25 Super-Woke Companies You Do Not Want in Your Portfolio with Alexander Green
  • Jeff Clark Trader: The Currency Trading Retirement Blueprint
  • Jason Williams Blue Gas: The Tesla Killer Fuel Cell Revolution
  • Andrew Zatlin: Biden’s Puppet Master Exposed and How to Opt Out of the Digital Dollar
  • The AI Takeover: Jason Bodner’s Quantum Edge Trader Smart Tech

Topics

AAPL Advertorial Amazon AMZN Artificial Intelligence Battery Bear Market Biotech Bitcoin Blockchain Clean Energy Cloud Computing Coronavirus COVID Creative Cryptocurrency Dividends E-Commerce Electric Vehicles Elon Musk Energy Ethereum Gold Growth Stocks Inflation Interest Rates International Jeff Brown Louis Navellier Market Crash MSFT Oil and Gas Options Prediction President Biden Recession Retirement Russia Semiconductor Supply Chain Tesla The Fed TSLA Volatility Warren Buffett

Copyright © 2023 · Stock Trend Alerts - Essential Market Moves and Investing Ideas

Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.

Stock Trend Alerts, its managers, its employees, affiliates and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.

The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. The Company is not affiliated with, nor does it receive compensation from, any specific security.

To the maximum extent permitted by law, the Company disclaims any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses.

About Us | How it Works | Privacy Policy | Terms and Conditions | Contact Us